Pemvidutide Phase 2b: dual agonism for MASH
Results from a Phase 2b trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) have been published in The Lancet. The trial demonstrated that the dual GLP-1/glucagon receptor agonist produced significant reductions in hepatic fat content and improvements in key histological markers of MASH, including fibrosis.
MASH (formerly NASH) is a progressive liver disease characterised by fat accumulation, inflammation, and fibrosis. It affects an estimated 5% of the global population and currently has very few approved pharmacological treatments. The condition is closely linked to obesity and metabolic syndrome, making GLP-1-based therapies a natural target.
Trial design and key findings
The randomised, placebo-controlled trial evaluated weekly subcutaneous pemvidutide at multiple dose levels in adults with biopsy-confirmed MASH and at least stage 1 fibrosis. The primary endpoint was change in liver fat content measured by MRI-PDFF.
At the highest dose, pemvidutide produced substantial reductions in liver fat content, with a significant proportion of participants achieving normalisation. Improvements in liver enzymes (ALT, AST) and non-invasive fibrosis scores were also observed. The results were statistically significant compared with placebo.
The glucagon receptor agonism component is particularly relevant for MASH: glucagon has direct effects on hepatic lipid metabolism, promoting fatty acid oxidation and reducing lipogenesis. Combined with GLP-1's effects on appetite and weight loss, the dual mechanism addresses multiple pathways implicated in MASH pathophysiology.
Safety profile
Adverse events were predominantly gastrointestinal — nausea, diarrhoea, and vomiting — consistent with GLP-1 receptor agonism. The safety profile was broadly comparable to other GLP-1-based therapies. Discontinuation rates were dose-dependent.
What it means for researchers
Pemvidutide, developed by Altimmune, is part of a growing class of dual and triple agonists targeting GLP-1, glucagon, and GIP receptors. The MASH Phase 2b data add to a body of evidence suggesting that glucagon receptor agonism may offer incremental benefit in liver disease beyond what GLP-1 agonism alone achieves.
The results position pemvidutide alongside other emerging MASH therapies, though it remains an investigational compound. Larger Phase 3 trials will be needed to confirm efficacy and safety, particularly for fibrosis improvement, which is the key regulatory endpoint for MASH therapies.
For UK researchers, the pemvidutide data illustrate the expanding therapeutic potential of multi-receptor peptide agonists beyond obesity and diabetes into hepatology. Pemvidutide is not licensed in the UK and remains under clinical investigation.
For a full compound profile and mechanism of action, see our pemvidutide profile.
This article is for research and educational purposes only. Pemvidutide is an investigational compound, not a licensed medicine. Nothing here constitutes medical advice.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.